Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13787342 | 0.93 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3970711 | 0.93 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL7875272 | 0.93 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12844684 | 0.93 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL11975717 | 0.93 | CTSB (0.37) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13563241 | 0.91 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13818122 | 0.91 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL11975791 | 0.91 | CTSB (0.38) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL11983952 | 0.91 | CTSB (0.35) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8221523 | 0.91 | CTSB (0.41) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106187-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-7910728-B2 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100036116-A1 | Process for the preparation of a macrocycle | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20090163706-A1 | Process for the preparation of a macrocycle | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163706-A1 | Process for the preparation of a macrocycle | CTRL, PREP, RNASE1 | CTSB 32/4885CTSS 19/4885ADRB3 4455/4885 |
| US-20100036116-A1 | Process for the preparation of a macrocycle | CTRL, PREP, RNASE1 | CTSB 32/4885CTSS 19/4885ADRB3 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.